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Participants: Sample Size 
(response rate%); Age; 
Women (%); data collection 
Participants Characteristics 
Settings 
Scenario: risk; medication; 







770 participants; 62% between 
40-59 years; 58% women; 
internet-based survey (in 
English) 
Community (18+; internet-
users); 90% educated to more 
than 12 years; 84% from 
USA; 23% GP or health 
professionals;  
Hypothetical; single choice 
experiment; high cholesterol 
level; daily statin-like; 10-year 
CV risk of angina or heart 
attack; side effects of statins; 
50US$ per month  
To decide whether to take the 
medication or not based on a 






2978 participants; 54% 
between 40-59 years; 59% 
women; internet-based survey 
(in English and Norwegian) 
Community (18+; internet-
users); 91% educated to more 
than 12 years; 42% from USA 
Hypothetical; single choice 
experiment; high cholesterol 
level; daily statin-like; 10-year 
CV risk of angina or heart 
attack; side effects of statins; 
50US$ per month 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 





1528 participants; 49% 
between 40-59 years; 53% 
women; internet-based survey 
(in Norwegian) 
Community (18+; internet-
users); 59% educated to 
university-level 
Hypothetical; single choice 
experiment; 40-yr old, non-
smoker, active and has a 
healthy diet; high blood 
pressure level; daily; 10-year 
CV risk of stroke or heart 
attack; dizziness, impotence 
nausea, muscle cramps and 
others; co-payment 
To decide whether to take the 
medication or not based on a 
single value of risk reduction, 




1367 participants (50%); mean 
age 60; 52% women; in-person 
interview 
Community (40+); 32% had 
elementary education only; 
5% history of heart attack and 
18% hypercholesterolemia 
Hypothetical; single choice 
experiment; high cholesterol 
level; daily; heart attack; few 
and harmless side effects; 
60€ per year 
To decide whether to take the 
medication or not based on a 




360 participants; mean age 38 
years; 50% women; face-to-
face interview 
Community; 22% on regular 
medications; 1% history of 
previous CVD  
Hypothetical; trade-off; high 
cholesterol level; daily statin-
like; CVD and death; no side 
effects; negligible 
Medical aversion (gain in 
lifespan required by participants 
to commence lifelong therapy); 




356 participants; mean age 76; 
75% women; in-person 
interview 
Community (senior centres); 
mean years of education was 
13; 69% had more than 3 
chronic conditions; 92% took 
1 or more medication, with a 
mean of 4 
Hypothetical; single choice 
experiment; multiple 
scenarios; primary CVD 
prevention; daily; 5-year MI 
risk; no side effects; covered 
by insurance 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 





100 participants (53%); mean 
66 years; 60% women; 
telephone interview 
Outpatients (4 family 
practices); patients eligible if 
they had heart disease and 
on statin;  
Hypothetical; single choice 
experiment; angina or heart 
attack; daily statin-like; 5-year 
heart attack risk; few side 
effects;  
To decide whether to take the 
medication or not based on a 
single value of risk reduction 





1201 participants (60%); 43% 
between 25-44 year; 48% 
women; face-to-face (or 
telephone) interview 
Community; 28% educated 
more than 12 years; 11% 
history of hypertension, 8% 
hypercholesterolemia 
Hypothetical; multiple choice 
experiment; multiple 
scenarios; angina or heart 
attack; daily statin-like; heart 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (3-
year NNT) 
 24 
attack or stroke; no serious 
side effects; cost comparable 





1397 participants (81%); mean 
58 years; 34% women; mailed 
questionnaire 
Community; 23% educated 
more than 12 years; 21% 
previous CVD history 
Hypothetical; single choice 
experiment; daily statin-like; 
heart attack; neither common 
nor dangerous side effects; 
refunded 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (5-




354 participants (36%); mean 
60 years; 44% women; mailed 
questionnaire 
Outpatients (3GPs, all 
registered 50-70 years); 31% 
educated to high school only; 
13% previous CVD history 
 
Hypothetical; single choice 
experiment; daily; death; no 
major side effects; 3$ per 3 
months 
To choose, from six different 
estimates (10-year NNT), the 
number of lives should be 





100 participants; 53% older 
than 55 years; 47% women; 
questionnaire 
Outpatients (35-65 years); 
55% take cardiovascular 
medications; 70% history of 
heart disease; 62% attended 
cardiology clinic 
Hypothetical; multiple choice 
experiment; daily statin-like; 
heart attack; negligible side 
effects; insured 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (5-




675 participants (60%); mean 
age 44 years; 51% women; 
face-to-face interview 
Community; 21% educated to 
elementary-level only; 3.3% 
previous CVD history 
Hypothetical; single choice 
experiment; daily; heart 
attack; few and mild side 
effects; co-payment 55$ per 
year 
To decide whether to take the 
medication or not based on a 




216 participants (41%); 40.5% 
between 50-69 years; 55% 
women; mailed questionnaire 
Outpatients (single GP); the 
mean age at which 
respondents finished 
education was 16.7 years; 
13% on antihypertensive 
medication; 2% previous MI 
Hypothetical; iterative 
process; anti-hypertensive 
daily; heart attack; some side 
effects; some payment 
To choose, from 6 different 
estimates (5-year NNT), the 
number of lives should be 
saved to justify lifelong 
medication; negative framing 
Marshall, 
2006, UK48  
203 participants; median age 
65; 13% women; face-to-face 
interview  
Outpatients (13 Practices, No 
CVD history); mean years of 
education 15.5; 34.5% on 
long-term oral medications; 
50% had less than 7.5% 5-
year coronary risk 
Hypothetical; multiple choice 
experiment; daily; heart 
disease; rare side effects;  
To decide whether to take the 
medication or not based on a 
single value of risk reduction (5-





74 participants (51%); mean 
age 49; 53% women; face-to-
face interview  
Outpatients (5 GPs and 4 
internists, mild hypertension; 
no overt CVD); 69% educated 
to more than 12 years; 65% 
on antihypertensive 
Hypothetical; multiple choice 
experiment; multiple 
scenarios; antihypertensive 
daily; death, MI, stroke;  
Iterative process to achieve the 
smallest benefit (ARR) that 




309 participants (102 
hypertensive, 207 
normotensive) (89%); aged 35-
65 years; mailed questionnaire 
Outpatients (single practice); 
patients excluded if illiterate, 
CVD, diabetes, disability, or 
mental illness  
Hypothetical; single choice 
experiment; anti-hypertensive-
like daily; stroke;  
To decide whether to take the 
medication or not based on a 




2326 participants (50%); mean 
age 47 years; 56% women; 
face-to-face interview 
Community; 26% educated to 
elementary-level 
Hypothetical; single choice 
experiment; multiple 
scenarios; daily; death or 
heart attack; out of pocket 
payment 
To decide whether to take the 
medication or not based on a 




384 participants (53%); mailed 
questionnaire 
Outpatients (1 GP) Hypothetical; single choice 
experiment; statin-like daily; 
MI 
To choose, from 4 different 
estimates (5-year NNT), the 
number of lives should be 
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1519 participants (49%); mean 
age 59; 53.9% women; face-
to-face interview 
Community; 6% previous 
heart attack; 17% 
hypercholesterolemia 
Hypothetical; single choice 
experiment; daily; death or 
heart attack; mild and 
harmless side effects; 45€ per 
year 
To decide whether to take the 
medication or not based on a 
single value of risk reduction (3-
year RRR with baseline risk) 
Steel, 2000, 
UK38 
58 participants (58%); 45% 41-
65 years old; 58% women  
Community (39 practices) Single choice experiment; 
anti-hypertensive medication 
To choose, from a five different 
estimates (5-year NNT), the 
number of lives should be 





1169 participants (37%); aged 
40-59; 57% women; face-to-
face interview 
Community; median years of 
education 13 years; 37% CVD 
history  
Hypothetical; single choice 
experiment; multiple 
scenarios; statin-like daily; 
fatal heart disease; out of 
pocket 
To decide whether to take the 
medication or not based on a 
single value of risk reduction 
(10-year ARR, NNT, POL) 
Trewby, 
2002, US33  
307 participants (97%); mean 
age 61 years; 42% women; 
face-to-face (or telephone) 
interview 
Both (3 groups: 1discharged 
from CCU; 2no MI history but 
on medication, 3neither 
history nor medication) 
Hypothetical; single choice 
experiment; statin-like daily; 
heart attack; safe 
Iterative process to achieve the 
minimum threshold (POL) that 
justify lifelong medication; 
extracted from Figure3 
